1 / 10

Health Services Research and Practice: Pharmaceuticals

Health Services Research and Practice: Pharmaceuticals. Andy Stergachis, Ph.D. R.Ph. Epidemiology and Pharmacy. Topics. Medication Use Variations in Drug-Related Services Pharmacoepidemiology & Drug Safety. Rx. Rx Expenditures: selected countries. $US Bil. Sales.

vincent-bernard
Download Presentation

Health Services Research and Practice: Pharmaceuticals

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Health Services Research and Practice: Pharmaceuticals Andy Stergachis, Ph.D. R.Ph. Epidemiology and Pharmacy

  2. Topics • Medication Use • Variations in Drug-Related Services • Pharmacoepidemiology & Drug Safety

  3. Rx Rx Expenditures: selected countries $US Bil Sales Source: IMS HEALTH: MIDAS, 2001 * Pharmacy only ** Hospital only

  4. Rx Rx Spending Per Capita Source: OECD Health Data, 1999

  5. Variations in Drug-Related Services • Pharmacies and pharmacists • Financing • Advertising and promotion • OTCs and drug schedules • Drug approval • Complementary medicine

  6. New Products 2001 Global Pipeline 6,225 To December 2001  8,722 Products 1,067 935 328 167 PRECLINICAL PRE-REG PHASE I PHASE II PHASE III 71% 11% 12% 4% 2% Source: IMS Lifecycle CD ROM December 2001

  7. Sources of Risk from Medical Products

  8. Pharmacoepidemiology as a Continuum • Surveillance/Signal Generation • Adverse event reports • Verify/Confirm and Quantify Risk • Case-control and cohort studies • Improved Patient Care and Regulatory Decision Making • Risk-to-benefit

  9. Issues • Affordability, access and equity • How safe is safe enough? • Variations in pharmacy practice • Variations in regulatory agencies • Drug reimportation concerns • Patterns of use, e.g., antimicrobial resistance

  10. More Information • www.fip.org: • Humanitarian Organizations (for example): • Other Organizations (eg. pharmacoepi.org) • stergach@u.washington.edu

More Related